Reduction in BCL-2 levels by 26S proteasome inhibition with bortezomib is associated with induction of apoptosis in small cell lung cancer

Phosphorylation Meets Ubiquitination: The Control of NF-κB Activity

2000 • 4,644 citations

The Bcl2 family: regulators of the cellular life-or-death switch

2002 • 3,782 citations

A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma

2003 • 2,642 citations

Akt/Protein Kinase B Up-regulates Bcl-2 Expression through cAMP-response Element-binding Protein

2000 • 778 citations

The development of proteasome inhibitors as anticancer drugs

2004 • 768 citations

To be, or not to be: NF-κB is the answer – role of Rel/NF-κB in the regulation of apoptosis

2003 • 738 citations

Development of the Proteasome Inhibitor Velcade™ (Bortezomib)

2004 • 629 citations

Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition.

2001 • 544 citations

The proteasome: a novel target for cancer chemotherapy

2002 • 530 citations

Transcriptional regulation of bcl-2 by nuclear factor κB and its significance in prostate cancer

2001 • 498 citations

Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma.

2001 • 481 citations

Regulation of apoptosis by bcl-2 family proteins and its role in cancer and chemoresistance

1995 • 481 citations

A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies.

2002 • 446 citations

Phase I Trial of the Proteasome Inhibitor Bortezomib in Patients With Advanced Solid Tumors With Observations in Androgen-Independent Prostate Cancer

2004 • 440 citations

Synergistic Induction of Oxidative Injury and Apoptosis in Human Multiple Myeloma Cells by the Proteasome Inhibitor Bortezomib and Histone Deacetylase Inhibitors

2004 • 383 citations

26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer

2001 • 263 citations

Role and Function of the 26S Proteasome in Proliferation and Apoptosis

2002 • 244 citations

Expression of bcl-2 in small cell lung carcinoma cells.

1994 • 222 citations

Small Cell Lung Cancer*

2003 • 219 citations

Chemosensitization of Pancreatic Cancer by Inhibition of the 26S Proteasome

2001 • 215 citations

Apoptosis in cancer: cause and cure

2000 • 207 citations

Bcl-2 family proteins as targets for anticancer drug design

2000 • 204 citations

Upregulation of bcl‐2 is involved in the mediation of chemotherapy resistance in human small cell lung cancer cell lines

2001 • 203 citations

NF-κB activates Bcl-2 expression in t(14;18) lymphoma cells

2002 • 182 citations

Inhibition of phosphatidylinositol 3-kinase-Akt signaling blocks growth, promotes apoptosis, and enhances sensitivity of small cell lung cancer cells to chemotherapy.

2002 • 168 citations

Phase I Study of G3139, a bcl-2 Antisense Oligonucleotide, Combined With Carboplatin and Etoposide in Patients With Small-Cell Lung Cancer

2004 • 167 citations

Expression of bcl‐2 oncogene protein is prevalent in small cell lung carcinomas

1995 • 167 citations

The function of multiple IκB : NF-κB complexes in the resistance of cancer cells to Taxol-induced apoptosis

2002 • 163 citations

Small cell carcinomas of the lung express the Bcl-2 protein.

1994 • 163 citations

Clinical update: proteasome inhibitors in solid tumors

2003 • 161 citations

Augmenting Chemosensitivity of Malignant Melanoma Tumors via Proteasome Inhibition

2004 • 159 citations

Fibroblast growth factor-2 induces translational regulation of Bcl-XL and Bcl-2 via a MEK-dependent pathway. CORRELATION WITH RESISTANCE TO ETOPOSIDE-INDUCED APOPTOSIS.

2015 • 156 citations

The presence of a constitutively active phosphoinositide 3-kinase in small cell lung cancer cells mediates anchorage-independent proliferation via a protein kinase B and p70s6k-dependent pathway.

1998 • 145 citations

Fibroblast Growth Factor-2 Induces Translational Regulation of Bcl-XL and Bcl-2 via a MEK-dependent Pathway

2002 • 143 citations

In vitro chemo- and radio-resistance in small cell lung cancer correlates with cell adhesion and constitutive activation of AKT and MAP kinase pathways

2002 • 137 citations

Proteasome inhibitor PS‐341 induces growth arrest and apoptosis of non‐small cell lung cancer cells via the JNK/c‐Jun/AP‐1 signaling

2004 • 133 citations

Rationale for the treatment of solid tumors with the proteasome inhibitor bortezomib

2003 • 126 citations

AKT inhibition is associated with chemosensitisation in the pancreatic cancer cell line MIA-PaCa-2

2003 • 113 citations

Expression and prognostic significance of kit, protein kinase B, and mitogen-activated protein kinase in patients with small cell lung cancer.

2003 • 111 citations

Effects of the proteasome inhibitor bortezomib alone and in combination with chemotherapy in the A549 non-small-cell lung cancer cell line

2004 • 100 citations

Not just research tools—proteasome inhibitors offer therapeutic promise

2002 • 98 citations

Bax to Bcl-2 Ratio and Ki-67 Index are Useful Predictors of Neoadjuvant Chemoradiation Therapy in Bladder Cancer

2004 • 94 citations

bcl-2/bax Ratio as a Predictive Marker for Therapeutic Response to Radiotherapy in Patients With Rectal Cancer

2001 • 73 citations

Novel functional PI 3‐kinase antagonists inhibit cell growth and tumorigenicity in human cancer cell lines

2000 • 72 citations

Recent advances in management of small-cell lung cancer

2004 • 71 citations

Bax:Bcl-2 ratio modulation by bryostatin 1 and novel antitubulin agents is important for susceptibility to drug induced apoptosis in the human early pre-B acute lymphoblastic leukemia cell line, Reh

1999 • 67 citations

Phosphatidylinositol 3′-Kinase, But Not S6-Kinase, Is Required for Insulin-Like Growth Factor-I and IL-4 To Maintain Expression of Bcl-2 and Promote Survival of Myeloid Progenitors

1999 • 55 citations

Treatment of small cell lung cancer patients

1999 • 40 citations

Bcl-2 as a Target for Overcoming Chemoresistance in Small-Cell Lung Cancer

2003 • 34 citations

Bcl-2 overexpression enhances in vitro sensitivity against docetaxel in non-small cell lung cancer.

2005 • 32 citations

Small Cell Lung Cancer: Current Therapy and Promising New Regimens

2002 • 27 citations

Bcl-2 Oncoprotein Expression Is Increased Especially in the Portion of Small Cell Carcinoma within the Combined Type of Small Cell Lung Cancer

1996 • 24 citations

The proteasome inhibitor, bortezomib, in combination with gemcitabine (Gem) and carboplatin (Carbo) in advanced non-small cell lung cancer (NSCLC): Final results of a phase I California Cancer Consortium study

2004 • 24 citations

Bcl-2 expression as a predictor of chemosensitivities and survival in small cell lung cancer.

1996 • 22 citations

Untitled

2001 • 21 citations

Small cell lung cancer: from molecular biology to novel therapeutics

2003 • 17 citations

Role ofBcl-2, Bax, andBak in spontaneous apoptosis and proliferation in neuroendocrine lung tumors: Immunohistochemical study

2000 • 14 citations

Treatment of small cell lung cancer patients.

1999 • 13 citations

Bcl-2 expression correlates with apoptosis induction but not loss of clonogenic survival in small cell lung cancer cell lines treated with etoposide

1998 • 12 citations

The proteasome inhibitor, bortezomib, in combination with gemcitabine (Gem) and carboplatin (Carbo) in advanced non-small cell lung cancer (NSCLC): Final results of a phase I California Cancer Consortium study

2004 • 10 citations